Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Silvia Maria Lavezzi"'
Autor:
Tae Eun Yang, Francesca Del Bene, Silvia Maria Lavezzi, Laura Iavarone, Jianping Zhang, Joseph Kim, Breanne Gjurich, Catherine Kessler
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 10, Pp 1722-1733 (2024)
Abstract The purpose of the analysis was to evaluate if 10 mg naloxone, administered intramuscularly, could reverse or prevent opioid‐induced respiratory depression (OIRD), including OIRD associated with the administration of lethal doses of high
Externí odkaz:
https://doaj.org/article/6ec5dd1f556e43ccbdc4e82c89924c8a
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 6, Pp n/a-n/a (2024)
Abstract The systemic exposure at the no‐observed‐adverse‐effect‐level (NOAEL) estimated from animals is an important criterion commonly applied to guard the safety of participants in clinical trials of investigational drugs. However, the dis
Externí odkaz:
https://doaj.org/article/58a999c5eead4fabaa55701bc86f924f
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background In drug development, few molecules from a large pool of early candidates become successful medicines after demonstrating a favourable benefit-risk ratio. Many decisions are made along the way to continue or stop the development of
Externí odkaz:
https://doaj.org/article/ed9e241284c5414e8122cc608a0e74fe
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 8, Pp 1029-1044 (2022)
Abstract Pharmacokinetic/pharmacodynamic (PK/PD) indices making use of area under the curve, maximum concentration, and the duration that in vivo drug concentration is maintained above a critical level are commonly applied to clinical dose prediction
Externí odkaz:
https://doaj.org/article/0fc13f2498c840dcbd96f6a923a4f6c4
Autor:
Letizia Carrara, Elisa Borella, Paolo Magni, Giuseppe De Nicolao, Silvia Maria Lavezzi, Italo Poggesi
Publikováno v:
Expert Opinion on Drug Discovery. :1-15
Pharmacometric models represent the most comprehensive approaches for extracting, summarizing and integrating information obtained in the often sparse, limited, and less-than-optimally designed experiments performed in the early phases of oncology dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c5fe1ec90a6edb0c02ae3b1f05bab4a
https://doi.org/10.1080/17460441.2017.1340271
https://doi.org/10.1080/17460441.2017.1340271
Autor:
Andre Goy, Mariya Salman, Italo Poggesi, Simon Rule, Michelle Mahler, Graeme Fraser, Olga Samoilova, Angela Howes, Paula Cramer, Siddhartha Ganguly, Javier Loscertales, Nancy L. Bartlett, Martine Neyens, Silvia Maria Lavezzi, Giuseppe De Nicolao, Fatih Demirkan, Jan de Jong, Marie Sarah Dilhuydy, Abraham Avigdor
Publikováno v:
Pharmaceutical Research. 36
In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f70d3db046e437539c6b2013c5b48eb
https://doi.org/10.1007/s11095-019-2605-8
https://doi.org/10.1007/s11095-019-2605-8
Publikováno v:
Computer methods and programs in biomedicine. 178
Background and objective In Duchenne Muscular Dystrophy (DMD) treatment, muscle fiber size can be considered as an indicator of muscle health and function. In particular, the statistical distribution of fibers cross-sectional areas (CSAs) has been us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85aabbf77628de6658fb39d7064bfeeb
https://pubmed.ncbi.nlm.nih.gov/31416560
https://pubmed.ncbi.nlm.nih.gov/31416560
Autor:
Stefano Zamuner, Monica Simeoni, Silvia Maria Lavezzi, Giuseppe De Nicolao, Enrica Mezzalana, Peiming Ma
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 45(6)
The aim of the present study was to evaluate model identifiability when minimal physiologically-based pharmacokinetic (mPBPK) models are integrated with target mediated drug disposition (TMDD) models in the tissue compartment. Three quasi-steady-stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01366170aa251ead1311e0f0270c12a7
https://pubmed.ncbi.nlm.nih.gov/30415351
https://pubmed.ncbi.nlm.nih.gov/30415351
Autor:
Elisa Borella, Letizia Carrara, Italo Poggesi, Silvia Maria Lavezzi, Paolo Magni, Giuseppe De Nicolao
Publikováno v:
Expert opinion on drug discovery. 13(1)
Drug attrition in oncology clinical development is higher than in other therapeutic areas. In this context, pharmacometric modeling represents a useful tool to explore drug efficacy in earlier phases of clinical development, anticipating overall surv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b3b72ed4b4c8e36795cd62e0045223
https://pubmed.ncbi.nlm.nih.gov/28972401
https://pubmed.ncbi.nlm.nih.gov/28972401
Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial
Autor:
Martine Neyens, Simon Rule, Giuseppe De Nicolao, Mariya Salman, Javier Loscertales, Abraham Avigdor, Italo Poggesi, Andre Goy, Michelle Mahler, Marie-Sarah Dilhuydy, Siddhartha Ganguly, Angela Howes, Olga Samoilova, Fatih Demirkan, Jan de Jong, Graeme Fraser, Alexander Pristupa, Silvia Maria Lavezzi, Nancy L. Bartlett, Paula Cramer
Background: Ibrutinib, an inhibitor of Bruton's tyrosine kinase, is indicated for the treatment of several B-cell malignancies. In the phase 3 HELIOS trial, the addition of ibrutinib to a bendamustine plus rituximab regimen significantly improved pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de497f7784ec1470c104cce5bd93ec15
https://avesis.deu.edu.tr/publication/details/ce8269ce-4e58-4d62-8ca5-d92bc489e843/oai
https://avesis.deu.edu.tr/publication/details/ce8269ce-4e58-4d62-8ca5-d92bc489e843/oai
